News | May 11, 2021
Vivimed Labs to manufacture, market Favipiravir tablets
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
These media reports are based on incorrect facts and are without any basis.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
